Eisai pushes second Alzheimer s drug despite call to probe U S approval of first japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.
Due to the late lifting of pandemic restrictions, the official Pride Run 5K can't be held in person, but organizers have planned several supplemental events.
Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer s Disease, Insomnia and Epilepsy
Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer s disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company s deep neurology pipeline and portfolio, including Alzheimer s disease, insomnia and epilepsy, will be presented at the 73
rd Annual Meeting of the American Academy of Neurology (AAN), taking place virtually from April 17-22, 2021.